Nutriband Inc. (NTRB)
5.51
-0.26 (-4.51%)
At close: Apr 03, 2025, 3:58 PM
5.95
8.02%
Pre-market: Apr 04, 2025, 07:03 AM EDT
Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.
Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices.
The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.
| Country | United States |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 South Orange Avenue Orlando, Florida United States | |
| Website | https://nutriband.com |
Stock Details
| Ticker Symbol | NTRB |
| Exchange | NASDAQ |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001676047 |
| CUSIP Number | 67092M208 |
| ISIN Number | US67092M2089 |
| Employer ID | 81-1118176 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Gareth Sheridan | Founder, Chief Executive Officer & Director |
| Dr. Alan Smith Ph.D. | Chief Operating Officer & President of 4P Therapeutics |
| Gerald Goodman | Chief Financial Officer & Chief Accounting Officer |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Michael Myer | President of Pocono Pharmaceutical |
| Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board |
| Tyler Overk | Head of Active Intelligence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | SCHEDULE 13D | Filing |
| Mar 13, 2025 | SCHEDULE 13D | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 16, 2024 | DEF 14A | Filing |
| Dec 04, 2024 | 10-Q | Quarterly Report |
| Dec 02, 2024 | 4 | Filing |
| Nov 29, 2024 | 4 | Filing |